Brief: Exact Therapeutics Gets Regulatory Approval To Start Dose Expansion Part Of Activate Study
31/07/2023 12:59
July 31 (Reuters) - Exact Therapeutics AS EXTX.OL :
* EXACT THERAPEUTICS RECEIVES REGULATORY APPROVAL TO START
THE
DOSE EXPANSION PART OF ACTIVATE STUDY
* UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
(MHRA)
HAS AWARDED ALL NECESSARY APPROVALS TO START DOSE EXPANSION PART
OF ACTIVATE STUDY
Source text for Eikon: ID:nObiZdR4ba
Further company coverage: EXTX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Exact Therapeutics AS
See all newsBrief: EXACT Therapeutics AS Gets Positive Safety Review For 60 Μl/Kg Dose In Phase 2 ENACT Trial
Brief: Exact Therapeutics Introduces New Long-Term Incentive Program
Brief: Exact Therapeutics H1 Operating Loss Widens To NOK 45.9 Million
Brief: Exact Therapeutics Announces Grant Of Core Patent In U.S.
Brief: Exact Therapeutics Announces Final Positive Data From Phase 1 Trial